Journal of Diabetes and Its Complications
Volume 25, Issue 2 , Pages 129-136 , March 2011

Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management

  • Vrushali S. Thorve

      Affiliations

    • Department of Pharmacology, AISSMS College of Pharmacy, Near R.T.O., Pune-411 001, India
    • ,
  • Ajay D. Kshirsagar

      Affiliations

    • Department of Pharmacology, AISSMS College of Pharmacy, Near R.T.O., Pune-411 001, India
    • Corresponding Author InformationCorresponding author. Department of Pharmacology, AISSMS College of Pharmacy, Kennedy Road, Near R.T.O., Pune-411 001, India. Tel.: +91 20 26058208; +91 8087306896 (Mob); fax: +91 20 26058208.
    • ,
  • Neeraj S. Vyawahare

      Affiliations

    • Department of Pharmacology, AISSMS College of Pharmacy, Near R.T.O., Pune-411 001, India
    • ,
  • Vipin S. Joshi

      Affiliations

    • Department of Pharmacognosy, AISSMS College of Pharmacy, Near R.T.O., Pune-411 001, India
    • ,
  • Kundan G. Ingale

      Affiliations

    • Department of Pharmacology, AISSMS College of Pharmacy, Near R.T.O., Pune-411 001, India
    • ,
  • Reshma J. Mohite

      Affiliations

    • Department of Pharmacology, AISSMS College of Pharmacy, Near R.T.O., Pune-411 001, India

Received 17 January 2010 ,Revised 16 March 2010 ,Accepted 29 March 2010.

References 

  1. Agarwal SK, Prakash A, Singh NP. Erectile dysfunction in diabetes mellitus: Novel treatments. Interantion Journal of Diabetes Development Countries. 2003;23:94–98
  2. Arie R, Ofra K, Yehuda K, Ella T, Juza C, Tamar S, et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: A community survey among 1,412 Israeli men. Clinical Cardiology. 2003;26:25–30
  3. Atul L, Anoop M. Erectile dysfunction in diabetic males: Plausible mechanisms and management strategies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2008;2:81–86
  4. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2005 and some possible policy consequences. BJU International. 1999;84:50–56
  5. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002;25:1458–1463
  6. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiological Review. 1995;75:725–748
  7. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes associated erectile dysfunction. Proceeding of the National Academy of Sciences of the United States of America. 2004;101:9121–9126
  8. Broderick GA, Lue TF. Evaluation and nonsurgical management of erectile dysfunction and priapism. In:  Walsh PC,  Retik AB,  Vaughan ED,  Wein AJ editor. Campbell's Urology. 8th ed.. Philadelphia: Saunders Publishers; 2002;p. 1619–1671
  9. Burke J, Jacobson D, McGree M, Nehra A, Roberts R, Girman C, et al. Diabetes and sexual dysfunction: Results from the Olmsted county study of urinary symptoms and health status among men. Journal of Urology. 2007;177:1438–1442
  10. Burns CN, Gingell C. Medical management of erectile dysfunction. Postgrad Med J. 1998;74:336–342
  11. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end- products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU International. 2001;87:402–407
  12. Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus — A nitric oxide dependent phenomenon. British Journal of Pharmacology. 1999;128:1804–1812
  13. Chang S, Hypolite JA, Velez M, Changolkar A, Wein AJ, Chacko S, et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. American Journal of Physiology Regulatory Integrative and Comparative Physiology. 2004;287:R950–R960
  14. Christ GJ, Gondrel CM, Melman A, Gradwood RC, Murray FT. Differential sensitivity of corporal smooth muscle from diabetic and nondiabetic patients to relaxation by potassium channel modulators. Journal of Andrology. 1995;16:55
  15. Christian GS, Stefan U, Udo J. Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part II). Journal of Men's Health. 2005;2:325–332
  16. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochemical and Biophysical Research Communications. 1992;186:867–873
  17. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. Journal of Urology. 2003;170:S35–S39
  18. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, et al. Erectile dysfunction in type 1 and type 2 diabetics in Italy. International Journal of Epidemiology. 2000;29:524–531
  19. Gerald B. Oral agents: First-line therapy for erectile dysfunction. European Urology Supplements. 2002;1:12–18
  20. Giuseppe C, Ferdinando F, Ciro I, Vincenzo M. Pharmacology of erectile dysfunction in man. Pharmacology & Therapeutics. 2006;111:400–423
  21. Goldstein I, Carson C, Rosen R, Islam A. Vasomax for the treatment of male erectile dysfunction. World Journal of Urology. 2001;19:51–56
  22. Guay A, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. Journal of Sexual Medicine. 2007;4:1046–1055
  23. Hartman U. The efficacy of psychosexual therapy for erectile dysfunction: A critical review of outcome studies. International Journal of Impotence Research. 1998;10(3):S23
  24. Haslett C, Chilvers ER, Boon NA, Colledge NR, Hunter JAA. In: Davidson's Principle and Practice of Medicine. 19th ed.. London: Churchill Livingstone; 2002;p. 641–682
  25. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: Which treatment for which patient?. Drugs. 2005;65:1621–1650
  26. Heaton, J. P., Adams, M. A., & Morales, A. (1996). Apomorphine SL effective in the treatment of non organic erectile dysfunction: Results of a multicenter trial. International Journal of Imporant Research, 8, A64, 115.
  27. Heaton JPW. Key issues from the clinical trials of apomorphine SL. World Journal of Urology. 2001;19:25–31
  28. Hedlund P, Aszodi A, Pfeifer A, Alm P, Hofmann F, Ahmad M, et al. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proceeding of the National Academy of Sciences of the United States of America. 2000;97:2349–2354
  29. Hilary K, Ronald EA, William HH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  30. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. Journal of Urology. 2000;163:460–463
  31. Kew-Kim C. Pharmacotherapy of erectile dysfunction: Current standards. Indian Journal of Urology. 2006;22:235–240
  32. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care. 1996;19:135–141
  33. Konstantinos H, Dimitrios H. Erectile dysfunction and diabetes mellitus. Insulin. 2009;4:114–122
  34. Kotera J, Grimes KA, Corbin JD, Francis SH. cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. Biochemical Journal. 2003;372:419–426
  35. Kumar V, Cotran RS, Robbins SL. In: Robbin's basic pathology. 7th ed.. Philadelphia: Saunders: An Imprint of Elsevier; 2004;p. 641–655
  36. Kwan KSH, Lindy JR, Delphin MS. Sexual dysfunction and chronic pain: The role of psychological variables and impact on quality of life. European Journal of Pain. 2005;9:643–652
  37. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA. 1999;281:537–544
  38. Lewis RW. Epidemiology of erectile dysfunction. Urologic Clinics of North America. 1996;28:209–216
  39. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980;18:279–283
  40. Mills TM, Pollock DM, Lewis RW, Branam HS, Wingard CJ. Endothelin-1-induced vasoconstriction is inhibited during erection in rats. American Journal of Physiology Regulatory Integrative and Comparative Physiology. 2001;281:R476–R483
  41. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Molecular and Cellular Biology. 2002;22:8467–8477
  42. Moemen MN, Hamed HA, Kamel II, Shamloul RM, Ghanem HM. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. International Journal of Imporant Research. 2004;16:143–145
  43. Moncada I, Martinez-Salamanca JI, Allona A, Hernandez C. Current role of penile implants for erectile dysfunction. Current Opinion in Urology. 2004;14:375–380
  44. Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. International Journal of Imporant Research. 2001;13:326–328
  45. Moore CR, Run W. Pathophysiology and treatment of diabetic erectile dysfunction. Asian Journal of Andrology. 2006;8(6):675–684
  46. Muammer K, Patrick ET, Hunter CC, Wayne JGH, Trinity JB. Gene therapy for erectile dysfunction: Fact or fiction?. European Urology. 2006;50:1208–1222
  47. Mulhall JP, Bukofzer S, Edmonds AL, George M the Apomorphine SL Study Group. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clinical Therapeutic. 2001;23:1260–1271
  48. Nraga RS, Braga LC. Chlorpromazine a good substitute drug for phentolamine: A follow up of 174 patients. International Journal of Imporant Research. 1996;8:113
  49. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New England Journal of Medicine. 1997;336:1–7
  50. Park JK, Lee SO, Kim YG, Kim SH, Koh GY, Cho KW. Role of rho-kinase activity in angiotensin II-induced contraction of rabbit clitoral cavernosum smooth muscle. International Journal of Imporant Research. 2002;14:472–477
  51. Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. International Journal of Imporant Research. 2000;12:S91–S100
  52. Price DE, Cooksey G, Jehu D, Bentley S, Hearnshaw JR, Osborn DE. The management of impotence in diabetic men by vacuum tumescence therapy. Diabetic Medicine. 1991;8:964–967
  53. Rees RW, Ziessen T, Ralph DJ, Kell P, Moncada S, Cellek S. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. International Journal of Imporant Research. 2002;14:1–7
  54. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy. 2000;26:191–208
  55. Savoca G, Silvestre G, Belgrano E. Intracavernosal injection therapy and surgical therapy in diabetic patients with erectile dysfunction. Diabetes Nutrition & Metabolism. 2002;15:53–57
  56. Sidi AA, Becher EF, Zhang G, Lewis JH. Patient acceptance of and satisfaction with an external negative pressure device for impotence. Journal of Urology. 1990;144:1154–1156
  57. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: A review. Diabetologia. 2001;44:129–146
  58. Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: Potential relevance to the pathogenesis of erectile dysfunction. Journal of Urology. 1997;158:1966–1972
  59. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990;33:306–310
  60. Vernet D, Cai L, Garban H, Babbit ML, Murray FT, Rajfer J, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (Type II) rats with erectile dysfunction. Endocrinology. 1995;136:5709–5717
  61. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carnae and aortic rings in vitro. American Journal of Cardiology. 1999;83:3C–12C
  62. Wang H, Eto M, Steers WD, Somlyo AP, Somlyo AV. RhoAmediated Ca2+ sensitization in erectile function. Journal of Biological Chemistry. 2002;277:30614–30621
  63. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  64. William OB, Anthony JB, Tom FL. Treatment options for erectile dysfunction. Endocrinology and Metabolism Clinics of North America. 2007;36:465–479

PII: S1056-8727(10)00042-5

doi: 10.1016/j.jdiacomp.2010.03.003

Journal of Diabetes and Its Complications
Volume 25, Issue 2 , Pages 129-136 , March 2011

Article Tools

* Image Usage & Resolution